Quantum Cyber (QUCY) Registration Filing summary
Event summary combining transcript, slides, and related documents.
Registration Filing summary
30 Nov, 2025Management team and governance
Board includes Guido Baechler (CEO), William Caragol (CFO), Dr. Heiner Dreismann, Gregory Tibbits, and Hans Hekland, with signatures dated December 9, 2024.
Directors and officers are indemnified to the fullest extent permitted by Dutch law, with liability insurance to be obtained prior to the offering.
Offering details and pricing
Up to 1,147,776 ordinary units (each with one ordinary share, one Class A warrant, and one Series B warrant) and up to 1,147,776 pre-funded units (each with a pre-funded warrant, one Class A warrant, and one Series B warrant) are being offered.
Up to 3,443,328 ordinary shares underlying the warrants and pre-funded warrants, totaling up to 4,591,104 ordinary shares in the offering.
Underwriters and syndicate
Maxim Group LLC is named as the placement agent in the placement agency agreement.
Latest events from Quantum Cyber
- Shareholders will vote on a $6M investment, board overhaul, and major capital structure changes.QUCY
Proxy Filing12 Mar 2026 - Offering up to $150M in securities to advance innovative cancer diagnostics amid high risk.QUCY
Registration Filing16 Dec 2025 - IPO aims to fund CRC diagnostics growth amid financial risk and Nasdaq compliance challenges.QUCY
Registration Filing29 Nov 2025 - Best-efforts offering seeks $5.33M for cancer diagnostics R&D and expansion, with high investor risk.QUCY
Registration Filing29 Nov 2025 - Offering up to $7.1M net to fund CRC diagnostics expansion, with high dilution and Nasdaq risks.QUCY
Registration Filing29 Nov 2025 - Raising up to $6M for cancer diagnostics, with high risk, dilution, and strong market potential.QUCY
Registration Filing29 Nov 2025 - Cancer diagnostics firm launches high-risk, dilutive best-efforts IPO to fund clinical and commercial growth.QUCY
Registration Filing29 Nov 2025 - Offering up to 30.8M shares/warrants to fund CRC diagnostics amid financial and Nasdaq risks.QUCY
Registration Filing29 Nov 2025 - Revenue up, losses down, and strategic focus sharpened for 2025 growth and FDA progress.QUCY
H1 202413 Jun 2025